Purification of Tregs from human blood
Step . | Cell type . | Total live cells . | CD4+ . | Tregs . | Treg yield, % . |
---|---|---|---|---|---|
Millions . | |||||
1 | PBMCs | 100 | 24.2 ± 9.4 | 1.96 ± 0.8 | |
2 | CD4+/CD127− | 19 ± 12 | 5.8 ± 7.3 | 1.55 ± 1.1 | |
3 | CD25+ (CD4+CD127−) | 0.61 ± 0.3 | 0.60 ± 8 | 0.59 ± 0.3 | 29.5 ± 4 |
Step . | Cell type . | Total live cells . | CD4+ . | Tregs . | Treg yield, % . |
---|---|---|---|---|---|
Millions . | |||||
1 | PBMCs | 100 | 24.2 ± 9.4 | 1.96 ± 0.8 | |
2 | CD4+/CD127− | 19 ± 12 | 5.8 ± 7.3 | 1.55 ± 1.1 | |
3 | CD25+ (CD4+CD127−) | 0.61 ± 0.3 | 0.60 ± 8 | 0.59 ± 0.3 | 29.5 ± 4 |
The total numbers of starting PBMCs were normalized to 100 million. Tregs were isolated using the CD4+CD25+CD127− Treg isolation kit II magnetic MicroBead method (Miltenyi Biotec). Data represent the yield of purified Tregs from normal human buffy coat cells. Shown are the means ± SD of 8 independent experiments.